Immunome (NASDAQ:IMNM) Shares Gap Down to $15.61

Immunome, Inc. (NASDAQ:IMNMGet Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $15.61, but opened at $15.20. Immunome shares last traded at $15.17, with a volume of 66,247 shares.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on IMNM shares. Guggenheim started coverage on Immunome in a report on Monday, April 15th. They set a “buy” rating and a $35.00 price target for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Wedbush increased their price objective on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research note on Monday, April 1st. SVB Leerink started coverage on shares of Immunome in a research note on Monday, January 29th. They set an “outperform” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has an average rating of “Buy” and a consensus price target of $30.50.

Get Our Latest Research Report on IMNM

Immunome Trading Down 5.5 %

The business has a 50-day moving average price of $19.98 and a 200 day moving average price of $15.70. The stock has a market capitalization of $884.12 million, a P/E ratio of -2.72 and a beta of 1.87.

Immunome (NASDAQ:IMNMGet Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $3.40 million. On average, sell-side analysts predict that Immunome, Inc. will post -1.91 earnings per share for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors have recently added to or reduced their stakes in the company. Dorsey Wright & Associates purchased a new position in Immunome in the 3rd quarter worth about $26,000. Jump Financial LLC purchased a new stake in shares of Immunome in the fourth quarter valued at approximately $172,000. Acadian Asset Management LLC purchased a new stake in shares of Immunome in the third quarter valued at approximately $414,000. Sei Investments Co. bought a new position in Immunome in the first quarter worth approximately $469,000. Finally, Clear Creek Financial Management LLC purchased a new position in Immunome during the 1st quarter worth $547,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Recommended Stories

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.